- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06441643
Rocklatan nouvelle génération
Une étude de phase II, prospective, en deux étapes, à double insu, randomisée, multicentrique, contrôlée, dose-réponse, évaluant l'innocuité et l'efficacité hypotensive oculaire des solutions ophtalmiques AR-17043 et PG043 (AR-17043/Latanoprost) chez des sujets Avec une pression intraoculaire élevée
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study consists of two sequential stages under a single protocol. Stage 1 and Stage 2 will enroll independent participant cohorts. Subject enrolled in Stage 1 will not be eligible to participate in Stage 2.
During Stage 1, approximately 100 adult subjects with OAG or OHT will be randomized to 5 arms: 3 different concentrations of AR-17043, placebo comparator, or netarsudil 0.02% (Rhopressa®) for a treatment duration of 7 days.
During Stage 2, approximately 350 adult subjects with OAG or OHT will be randomized to 5 arms: low and high concentrations of PG043 (AR-17043/latanoprost 0.005%), AR-17043 high concentration, latanoprost, or netarsudil 0.02%/latanoprost 0.005% (Rocklatan®) for a treatment duration of 28 days.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Alabama
-
Dothan, Alabama, États-Unis, 36301
- Trinity Research Group
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85003
- Eye Doctors of Arizona
-
-
California
-
Garden Grove, California, États-Unis, 92843
- Orange County Ophthalmology Medical Group
-
Inglewood, California, États-Unis, 90301
- United Medical Research Institute
-
Newport Beach, California, États-Unis, 92663
- Eye Research Foundation
-
Petaluma, California, États-Unis, 94954
- North Bay Eye Associates
-
-
Colorado
-
Fort Collins, Colorado, États-Unis, 80528
- Eye Center of Northern Colorado, PC
-
-
Florida
-
Delray Beach, Florida, États-Unis, 33484
- Glaucoma Specialists of South Florida
-
Delray Beach, Florida, États-Unis, 33484
- Bruce A. Segal MD
-
Lakeland, Florida, États-Unis, 33805
- Central Florida Eye Associates
-
Mt. Dora, Florida, États-Unis, 32757
- Mid Florida Eye Center
-
Venice, Florida, États-Unis, 34285
- Center For Sight
-
-
Georgia
-
Roswell, Georgia, États-Unis, 30076
- Coastal Research Associates
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64154
- Moyes Eye Center
-
-
New York
-
Rochester, New York, États-Unis, 14618
- Rochester Ophthalmological Group
-
-
North Carolina
-
Winston-Salem, North Carolina, États-Unis, 27101
- James D. Branch Ophthalmology
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58103
- Bergstrom Eye Research
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45242
- Cincinnati Eye Institute
-
Cincinnati, Ohio, États-Unis, 45236
- Midwest Eye Center
-
-
Pennsylvania
-
Cranberry Township, Pennsylvania, États-Unis, 16066
- Scott & Christie and Associates, PC
-
-
South Carolina
-
Mt. Pleasant, South Carolina, États-Unis, 29464
- Carolina Eyecare Physicians LLC
-
-
Tennessee
-
Maryville, Tennessee, États-Unis, 37803
- University Eye Specialists
-
Memphis, Tennessee, États-Unis, 38119
- Total Eye Care PA
-
-
Texas
-
Dallas, Texas, États-Unis, 75243
- Key-Whitman Eye Center
-
-
Virginia
-
Lynchburg, Virginia, États-Unis, 24502
- Piedmont Eye Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Stage 1 Key Inclusion Criteria;
- Diagnosis of OAG or OHT in both eyes.
- High unmedicated IOP measurements in the study eye as specified in the protocol.
- Corrected visual acuity equal to or better than +1.0 logMAR (Snellen equivalent equal to or better than 20/200) in the study eye.
- Other protocol-specified inclusion criteria may apply.
Stage 2 Key Inclusion Criteria:
- Diagnosis of OAG or OHT in both eyes.
- High unmedicated IOP measurements in the study eye as specified in the protocol.
- Corrected visual acuity equal to or better than +0.7 logMAR (Snellen equivalent equal to or better than 20/100) in the study eye.
- Other protocol-specified inclusion criteria may apply.
Stage 1 and Stage 2 Key Exclusion Criteria:
- Current use of more than 2 ocular hypotensive medications within 30 days (either eye).
- Intraocular pressure greater than 36 millimeters mercury (mmHg) at Screening.
- Glaucoma other than OAG.
- Previous glaucoma surgery.
- Any abnormality preventing reliable measurements.
- Unable to demonstrate proper eyedrop instillation.
- Other protocol-specified exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: AR-17043 low concentration (Stage 1)
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Investigational monotherapy |
|
Expérimental: AR-17043 medium concentration (Stage 1)
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Investigational monotherapy |
|
Expérimental: AR-17043 high concentration (Stage 1)
AR-17043 Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Investigational monotherapy |
|
Comparateur placebo: AR-17043 vehicle (Stage 1)
AR-17043 Vehicle, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Placebo comparator |
|
Comparateur actif: Rhopressa (Stage 1)
Netarsudil 0.02% Ophthalmic Solution, one drop in each eye in the morning on Day 1, followed by one drop in each eye in the evening on Days 2-7. |
Marketed monotherapy
Autres noms:
|
|
Expérimental: PG043 low concentration (Stage 2)
PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Investigational fixed dose combination |
|
Expérimental: PG043 high concentration (Stage 2)
PG043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Investigational fixed dose combination |
|
Comparateur actif: AR-17043 high concentration (Stage 2)
AR-17043 Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Investigational monotherapy |
|
Comparateur actif: Latanoprost (Stage 2)
Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Marketed monotherapy
Autres noms:
|
|
Comparateur actif: Rocklatan (Stage 2)
Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution, one drop in each eye in the evening on Days 1-28. |
Marketed fixed dose combination
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean diurnal IOP at Day 8 (Stage 1)
Délai: Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the four measurements. |
Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean diurnal IOP at Day 29 (Stage 2)
Délai: Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. Diurnal IOP will be calculated as the average of the three measurements. |
Day 29 (8:00, 10:00, 16:00)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Mean IOP at each post-treatment timepoint (Stage 1)
Délai: Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint. |
Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean change from the diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 1)
Délai: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean percent change from diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 1)
Délai: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)
Délai: Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the four baseline measurements. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 12:00, 16:00), Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean percent change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 1)
Délai: Baseline (8:00, 10:00, 12:00, 16:00); Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the four baseline measurements. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 12:00, 16:00); Day 1 (8:00, 10:00, 12:00), Day 8 (8:00, 10:00, 12:00, 16:00)
|
|
Mean IOP at each post-treatment timepoint (Stage 2)
Délai: Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint. |
Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
|
Mean change from the diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 2)
Délai: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
|
Mean percent change from diurnally adjusted baseline IOP at each post-treatment timepoint (Stage 2)
Délai: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer at each post-treatment timepoint and compared to the time-relevant (corresponding) baseline measurement. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
|
Mean change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 2)
Délai: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the three baseline measurements. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
|
Mean percent change from baseline mean diurnal IOP at each post-treatment timepoint (Stage 2)
Délai: Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Intraocular pressure (IOP) will be measured with a Goldmann tonometer. The baseline mean diurnal IOP will be calculated as the average of the three baseline measurements. Baseline is defined as the last visit prior to initiation of treatment. |
Baseline (8:00, 10:00, 16:00); Day 8 (8:00, 10:00, 16:00); Day 15 (8:00, 10:00, 16:00); Day 29 (8:00, 10:00, 16:00)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Clinical Trial Lead, Pharma, Alcon Research, LLC
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies oculaires
- Glaucome
- Glaucome à angle ouvert
- Hypertension oculaire
- Solutions pharmaceutiques
- Préparations pharmaceutiques
- Acides gras
- Lipides
- Actions pharmacologiques
- Actions et utilisations chimiques
- Utilisations thérapeutiques
- Facteurs biologiques
- Solutions
- Utilisations spéciales de produits chimiques
- Prostaglandines F, synthétique
- Prostaglandines, synthétique
- Prostaglandines
- Eicosanoïdes
- Acides gras, insaturés
- Autacoïdes
- Médiateurs d'inflammation
- Latanoprost
- Solutions ophtalmiques
- Netarsudil
Autres numéros d'identification d'étude
- GLR305-E001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .